

ENROLLMENT

Assessed for eligibility N = 372

Excluded N = 290
 Did not meet criteria (132)
 Declined to participate (129)
 Other reasons (29)

Invited for intake N = 82

INCLUSION

Inclusion

Excluded after intake N = 3
 Declined further participation

Randomized into treatment

ADHD^{Active}
 N=20

RG^{Active}
 N=20

ADHD^{Placebo}
 N=20

RG^{Placebo}
 N=19

DESIGN & FOLLOW-UP

Baseline

- fMRI*
Go/NoGo-task
- Physiology*
Urine sampling
Cheekcell sampling
EFAQ
- Behavior*
CBCL
SWAN
- Compliance*
DLCQ
Weighing of test product

Interim Visit 1
 DLCQ
 SWAN

Interim Visit 2
 DLCQ
 SWAN

Interim Visit 3
 DLCQ
 SWAN

16-week intervention

Double-blind randomized placebo-controlled
 2x2 factorial design

Follow-up

- fMRI*
Go/NoGo-task
- Physiology*
Urine sampling
Cheekcell sampling
EFAQ
- Behavior*
CBCL
SWAN
- Compliance*
DLCQ
Weighing of leftover product

ADHD^{Active}
 N=19

RG^{Active}
 N=20

ADHD^{Placebo}
 N=19

RG^{Placebo}
 N=18

Excluded from analysis
 Non-compliance (1)

Lost to follow-up
 Adverse event (1)

Lost to follow-up
 Drop-out (1)